Previous studies have shown that STAT3 inhibition can sensitize cervical cancer to growth inhibition and apoptosis induced by cisplatin, a common therapeutic used to treat these cancers [39,40] Furthermore, ruxolitinib has also been demonstrated to synergise with cisplatin in HNSCC and non-small cell lung carcinoma (NSCLC) [41,42]. Here, STAT3 is linked to cervical carcinoma.